LANCE A SLOAN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
- Where
- LUFKIN, TX
- NPI
- 1588665228
- Received
- $1,774,173 in 2,776 records, 2019 to 2025 ($1,742,301 general, $31,871 research)
- As principal investigator
- $1,918,212 of research payments to others in 264 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 384 | $235,847 |
| 2025 | Research payment | 7 | $984 |
| 2024 | General payment | 449 | $360,442 |
| 2024 | Research payment | 1 | $8,938 |
| 2023 | General payment | 334 | $186,189 |
| 2023 | Research payment | 10 | $1,955 |
| 2022 | General payment | 252 | $127,705 |
| 2022 | Research payment | 7 | $3,287 |
| 2021 | General payment | 324 | $202,742 |
| 2020 | General payment | 321 | $172,406 |
| 2019 | General payment | 672 | $456,967 |
| 2019 | Research payment | 15 | $16,705 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 559 | $1,257,206 |
| Travel and Lodging | 621 | $208,727 |
| Consulting Fee | 58 | $171,902 |
| Food and Beverage | 1,472 | $65,054 |
| Research payment | 40 | $31,871 |
| Honoraria | 5 | $24,335 |
| Compensation for serving as faculty or as a speaker for a medical education program | 5 | $9,731 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $5,100 |
| Education | 15 | $244 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $334 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $143 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $101 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $88 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-18 | Calliditas Therapeutics US Inc. | $30 | Food and Beverage | In-kind items and services | TARPEYO Drug, NEPHROLOGY | 2025 | |
| 2025-12-17 | Corcept Therapeutics | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-17 | Corcept Therapeutics | $328 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-17 | Corcept Therapeutics | $90 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-17 | Corcept Therapeutics | $15 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-16 | CeQur Corporation | $16 | Food and Beverage | Cash or cash equivalent | CeQur Simplicity Device, Diabetes | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $3,430 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $112 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $108 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Ascendis Pharma Endocrinology Inc | $29 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-05 | Corcept Therapeutics | $77 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-04 | Novo Nordisk Inc | $52 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $616 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $373 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $368 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $172 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $137 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $120 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $55 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $50 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $29 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Corcept Therapeutics | $17 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-03 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | Filspari Drug, Kidney Disease | 2025 | |
| 2025-12-02 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-11-25 | Corcept Therapeutics | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-25 | Corcept Therapeutics | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,562 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-23 | Ascendis Pharma Endocrinology Inc | $74 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-11-21 | Corcept Therapeutics | $136 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-20 | Corcept Therapeutics | $732 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-20 | Corcept Therapeutics | $488 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-20 | Corcept Therapeutics | $467 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-20 | Corcept Therapeutics | $125 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-19 | Corcept Therapeutics | $2,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-19 | Bayer Healthcare Pharmaceuticals Inc. | $7 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-17 | Madrigal Pharmaceuticals | $30 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-13 | Corcept Therapeutics | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-13 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-13 | Bayer Healthcare Pharmaceuticals Inc. | $1 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-12 | Novo Nordisk Inc | $37 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-11-11 | Travere Therapeutics, Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-11 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | Filspari Drug, Kidney Disease | 2025 | |
| 2025-11-10 | Corcept Therapeutics | $24 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-09 | AstraZeneca Pharmaceuticals LP | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-08 | Genentech USA, Inc. | $66 | Food and Beverage | In-kind items and services | Gazyva Biological, BioOncology | 2025 | |
| 2025-11-07 | Travere Therapeutics, Inc. | $72 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-07 | Recor Medical Inc | $47 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-11-06 | Travere Therapeutics, Inc. | $124 | Food and Beverage | In-kind items and services | Filspari Drug, Kidney Disease | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $227 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $117 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-05 | BETA BIONICS, INC. | $13 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $413 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $117 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-29 | Corcept Therapeutics | $519 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | Corcept Therapeutics | $359 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | Corcept Therapeutics | $304 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | Corcept Therapeutics | $215 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | Corcept Therapeutics | $80 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-29 | RECORDATI_RARE_DISEASES_INC. | $32 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-10-29 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-28 | Ascensia Diabetes Care Us Inc. | $43 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-27 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | Filspari Drug, Kidney Disease | 2025 | |
| 2025-10-24 | Travere Therapeutics, Inc. | $418 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | Lilly USA, LLC | $73 | Food and Beverage | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $11 | Food and Beverage | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-22 | Corcept Therapeutics | $2,800 | Honoraria | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-21 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NGENLA Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2025 | |
| 2025-10-17 | Lilly USA, LLC | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-15 | Corcept Therapeutics | $241 | Travel and Lodging | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-15 | Corcept Therapeutics | $55 | Food and Beverage | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-15 | Travere Therapeutics, Inc. | $1 | Education | In-kind items and services | Filspari Drug, Kidney Disease | 2025 | |
| 2025-10-13 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-10-11 | Travere Therapeutics, Inc. | $240 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $240 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $149 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $73 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $49 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $45 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-11 | Travere Therapeutics, Inc. | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-09 | Lilly USA, LLC | $2,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-09 | Lilly USA, LLC | $1,995 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-09 | PFIZER INC. | $1,450 | Consulting Fee | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | 2025 | |
| 2025-10-08 | PFIZER INC. | $906 | Consulting Fee | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | 2025 | |
| 2025-10-08 | Bayer Healthcare Pharmaceuticals Inc. | $176 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-08 | Bayer Healthcare Pharmaceuticals Inc. | $101 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $78 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-08 | Bayer Healthcare Pharmaceuticals Inc. | $27 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-08 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-07 | Tandem Diabetes Care, Inc. | $19 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-10-06 | Eli Lilly and Company | $180 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | Eli Lilly and Company | $178 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-06 | Insulet Corporation | $26 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $258 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $66 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-02 | Lilly USA, LLC | $512 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Lilly USA, LLC | $502 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Lilly USA, LLC | $417 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Lilly USA, LLC | $353 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | Lilly USA, LLC | $197 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-01 | Corcept Therapeutics | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-01 | Corcept Therapeutics | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-01 | Corcept Therapeutics | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-01 | Corcept Therapeutics | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-01 | Novo Nordisk Inc | $1,965 | Consulting Fee | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-01 | Novo Nordisk Inc | $655 | Consulting Fee | Cash or cash equivalent | Ozempic Drug, Diabetes | 2025 | |
| 2025-10-01 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-30 | Medtronic, Inc. | $103 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-09-27 | Bayer Healthcare Pharmaceuticals Inc. | $5,585 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-27 | Corcept Therapeutics | $75 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-27 | Corcept Therapeutics | $49 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-27 | Corcept Therapeutics | $48 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-27 | Corcept Therapeutics | $26 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-27 | Corcept Therapeutics | $26 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-26 | Corcept Therapeutics | $690 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-26 | Corcept Therapeutics | $408 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-25 | Corcept Therapeutics | $151 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-25 | Corcept Therapeutics | $52 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-25 | Corcept Therapeutics | $35 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $7,000 | Honoraria | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $2,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $711 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $162 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $124 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-24 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-23 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $148 | Travel and Lodging | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $97 | Travel and Lodging | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $37 | Food and Beverage | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $33 | Food and Beverage | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-18 | Lilly USA, LLC | $29 | Travel and Lodging | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-17 | Corcept Therapeutics | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-16 | Lilly USA, LLC | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-15 | Corcept Therapeutics | $29 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-12 | Lilly USA, LLC | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-11 | Corcept Therapeutics | $536 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-11 | Corcept Therapeutics | $344 | Travel and Lodging | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-11 | Bayer Healthcare Pharmaceuticals Inc. | $95 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-11 | Madrigal Pharmaceuticals | $18 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-09-08 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-09-08 | Insulet Corporation | $11 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-09-03 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-09-03 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NGENLA Drug, ENDOCRINE DISEASE;METABOLIC DISEASE | 2025 | |
| 2025-09-02 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-02 | Globus Medical, Inc. | $17 | Food and Beverage | Cash or cash equivalent | Senza Device, SPINAL CORD STIMULATOR | 2025 | |
| 2025-08-26 | Lilly USA, LLC | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-25 | Lilly USA, LLC | $2,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-25 | Lilly USA, LLC | $1,995 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-21 | Lilly USA, LLC | $436 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-21 | Lilly USA, LLC | $426 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-21 | Lilly USA, LLC | $95 | Food and Beverage | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-20 | Corcept Therapeutics | $2,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-20 | Corcept Therapeutics | $1,155 | Honoraria | Cash or cash equivalent | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-20 | Ascendis Pharma Endocrinology Inc | $22 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-08-20 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-19 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $275 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $161 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $48 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-15 | Lilly USA, LLC | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-13 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-12 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-06 | Bayer Healthcare Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-05 | Corcept Therapeutics | $25 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-05 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-08-02 | Ionis Pharmaceuticals, Inc. | $91 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-30 | RECORDATI_RARE_DISEASES_INC. | $19 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-28 | Insulet Corporation | $23 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-24 | Lilly USA, LLC | $147 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-24 | Lilly USA, LLC | $44 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-24 | Lilly USA, LLC | $27 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-24 | Lilly USA, LLC | $21 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-23 | Lilly USA, LLC | $43 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-23 | Lilly USA, LLC | $27 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-23 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-07-22 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-07-21 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-07-17 | Lilly USA, LLC | $60 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Lilly USA, LLC | $42 | Travel and Lodging | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Lilly USA, LLC | $14 | Food and Beverage | Cash or cash equivalent | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-07-17 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-07-16 | Xeris Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-07-14 | Madrigal Pharmaceuticals | $120 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 |
The latest 200 records of 2,776.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $10,020 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-11-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $40,061 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-11-17 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $5,065 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-10-22 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $14,645 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-09-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $40,061 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-09-08 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $17,905 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $40,061 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-08-18 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $6,360 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-07-07 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $13,435 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-06-09 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $26,960 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-05-12 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $8,170 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-04-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $13,353 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-04-09 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $15,290 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-03-12 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $17,670 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-02-25 | Eli Lilly and Company | LANCE SLOAN, | $289 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-02-21 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $31,904 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiova | 2025 |
| 2025-02-14 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $6,540 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2025-01-21 | Eli Lilly and Company | LANCE SLOAN, | $41,105 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 |
| 2025-01-21 | Eli Lilly and Company | LANCE SLOAN, | $24,677 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-01-13 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $9,810 | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase in | 2025 |
| 2024-09-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $78,073 | Phase III Renal Outcomes | 2024 |
| 2024-07-23 | Eli Lilly and Company | LANCE SLOAN, | $29,302 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-07-03 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $45,175 | Phase III Renal Outcomes | 2024 |
| 2024-06-25 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $2,802 | 20170625_VESALIUS - CV | 2024 |
| 2024-05-10 | Eli Lilly and Company | LANCE SLOAN, | $198 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-01-25 | Eli Lilly and Company | LANCE SLOAN, | $240 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2024-01-10 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $14,700 | EMPA-KIDNEY | 2024 |
| 2024-01-08 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $27,014 | 20170625_VESALIUS - CV | 2024 |
| 2024-01-02 | Eli Lilly and Company | LANCE SLOAN, | $30,456 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2023-10-17 | SANOFI US SERVICES INC. | Texas Institute For Kidney And Endocrine Disorders | $1,250 | A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargi | 2023 |
| 2023-09-12 | SANOFI US SERVICES INC. | Texas Institute For Kidney And Endocrine Disorders | $1,500 | A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargi | 2023 |
| 2023-07-13 | SANOFI US SERVICES INC. | Texas Institute For Kidney And Endocrine Disorders | $4,250 | A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargi | 2023 |
| 2023-06-26 | GlaxoSmithKline, LLC. | Texas Institute For Kidney And Endocrine Disorders | $127 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, | 2023 |
| 2023-05-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Texas Institute For Kidney And Endocrine Disorders | $8,381 | BI 685509 Dose finding PoCC in DKD | 2023 |
| 2023-04-17 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $8,900 | EMPA KIDNEY | 2023 |
| 2023-04-04 | Eli Lilly and Company | LANCE SLOAN | $62,031 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2023-03-10 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $1,955 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2023 |
| 2023-02-06 | Amgen Inc. | TEXAS INST FOR KIDNEY & ENDOCRINE DISORDERS | $13,955 | 20170625_VESALIUS - CV | 2023 |
| 2023-01-10 | Eli Lilly and Company | LANCE SLOAN | $604 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2022-11-17 | Eli Lilly and Company | UPSTATE MEDICAL UNIVERSITY | $562 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2022 |
| 2022-11-08 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $6,562 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-11-01 | Eli Lilly and Company | LANCE SLOAN, | $456 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2022 |
| 2022-10-31 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $6,116 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-09-26 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $2,585 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-09-08 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $2 | BI 685509 Dose finding PoCC in Non Diabetic CKD | 2022 |
| 2022-05-25 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $13,577 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-04-19 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $3,362 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-03-22 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $453 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-22 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $707 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-22 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $10,641 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-22 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $324 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-21 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $1,935 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2022 |
| 2022-03-03 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $1,000 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-03 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $12,001 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-03-02 | GlaxoSmithKline, LLC. | LANCE SLOAN MD AND ENDOCRINE DISORDERS | $360 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2022 |
| 2022-02-15 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $7,143 | 20170625_VESALIUS - CV | 2022 |
| 2022-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Texas Institute For Kidney And Endocrine Disorders | $37,253 | BI 685509 Dose finding PoCC in DKD | 2022 |
| 2022-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $30,497 | EMPA KIDNEY | 2022 |
| 2022-01-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $1,498 | BI 685509 Dose finding PoCC in DKD | 2022 |
| 2022-01-24 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $34,805 | EMPA KIDNEY | 2022 |
| 2022-01-22 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $1,401 | 20170625_VESALIUS - CV | 2022 |
| 2022-01-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Texas Institute For Kidney And Endocrine Disorders | $5,100 | BI 685509 Dose finding PoCC in Non Diabetic CKD | 2022 |
| 2021-12-31 | Merck Sharp & Dohme LLC | Texas Institute For Kidney And Endocrine Disorders | $664 | A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | Texas Institute For Kidney And Endocrine Disorders | $32,620 | A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial | 2021 |
| 2021-12-22 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $3,275 | EMPA-KIDNEY | 2021 |
| 2021-12-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $3 | BI 685509 Dose finding/PoCC in DKD | 2021 |
| 2021-12-01 | GlaxoSmithKline, LLC. | SLOAN LANCE A OFFICE | $318 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2021 |
| 2021-12-01 | GlaxoSmithKline, LLC. | SLOAN LANCE A OFFICE | $2,485 | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | 2021 |
| 2021-11-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $12,198 | EMPA-KIDNEY | 2021 |
| 2021-11-29 | Janssen Research & Development, LLC | TEXAS INSTITUTE FOR KIDNEY AND ENDO CRINE DISORDERS | $6,993 | A Randomized Multi Center Double Blind Parallel Group Placebo Controlled Study to Investigate the Efficacy and Safety of | 2021 |
| 2021-11-19 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $4,585 | EMPA-KIDNEY | 2021 |
| 2021-11-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $1,366 | BI 685509 Dose finding/PoCC in DKD | 2021 |
| 2021-10-31 | Amgen Inc. | Texas Institute For Kidney And Endocrine Disorders | $275 | (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | 2021 |
| 2021-10-27 | Boehringer Ingelheim International GmbH | Texas Institute For Kidney And Endocrine Disorders | $3,930 | EMPA-KIDNEY | 2021 |
| 2021-10-26 | Boehringer Ingelheim Limited | Texas Institute For Kidney And Endocrine Disorders | $425 | BI 685509 Dose finding/PoCC in Non-Diabetic CKD | 2021 |
| 2021-10-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | Texas Institute For Kidney And Endocrine Disorders | $33 | BI 685509 Dose finding/PoCC in DKD | 2021 |
| 2021-10-15 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $4 | EX6018-4758 | 2021 |
| 2021-10-15 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $7 | EX6018-4758 | 2021 |
| 2021-10-15 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $11 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $75 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $9 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $14 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
| 2021-10-11 | Novo Nordisk AS | Texas Institute For Kidney And Endocrine Disorders | $2 | EX6018-4758 | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lufkin, TX, county Angelina County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Lufkin, TX | County Angelina County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 34,251 | 87,275 | 30,188,424 |
| Population, 2020 census P1 | 34,143 | 86,395 | 29,145,505 |
| Median age B01002 | 34.6 | 37.8 | 35.6 |
| Under 18 B01001 | 27.2% | 25.3% | 25.0% |
| 65 and over B01001 | 15.2% | 16.9% | 13.4% |
| Households B11001 | 12,912 | 32,271 | 10,992,816 |
| Foreign born B05002 | 12.6% | 8.0% | 17.6% |
| Median household income B19013 | $57,048 | $60,960 | $78,476 |
| Median family income B19113 | $72,115 | $74,557 | $94,599 |
| Per capita income B19301 | $28,636 | $29,614 | $40,752 |
| Poverty rate B17001 | 18.0% | 15.8% | 13.8% |
| Unemployment rate B23025 | 7.0% | 6.4% | 5.3% |
| Civilian labor force B23025 | 15,657 | 39,764 | 15,233,563 |
| Mean commute (minutes) B08013 | 17.2 | 20.9 | 26.7 |
| Bachelor's degree or higher B15003 | 21.8% | 17.9% | 33.8% |
| Housing units B25001 | 14,555 | 37,023 | 12,128,515 |
| Owner-occupied B25003 | 51.6% | 64.0% | 62.6% |
| Renters B25003 | 48.4% | 36.0% | 37.4% |
| Median home value B25077 | $179,600 | $163,500 | $283,800 |
| Median gross rent B25064 | $1,079 | $1,076 | $1,403 |
| White, not Hispanic B03002 | 42.4% | 58.2% | 39.1% |
| Black B03002 | 18.3% | 12.1% | 11.9% |
| Hispanic or Latino B03002 | 33.8% | 23.5% | 39.7% |
| Asian B03002 | 1.8% | 0.9% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.3% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lufkin, TX.
Comments